نتایج جستجو برای: lenalidomide

تعداد نتایج: 3060  

2014
Tatyana Feldman Anthony R Mato Kar F Chow Ewelina A Protomastro Kara M L Yannotti Pritish Bhattacharyya Xiao Yang Michele L Donato Scott D Rowley Carolanne Carini Marisa Valentinetti Judith Smith Gabriella Gadaleta Coleen Bejot Susan Stives Mary Timberg Sabrina Kdiry Andrew L Pecora Anne W Beaven Andre Goy

Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is associated with a poor prognosis. Outcomes are particularly poor following immunochemotherapy failure or relapse within 12 months of induction. We conducted a Phase I/II trial of lenalidomide plus RICE (rituximab, ifosfamide, carboplatin, and etoposide) (RICER) as a salvage regimen for first-relapse or primary refractory DLBCL. Dose-e...

Journal: :Blood 2011
Sarah E M Herman Rosa Lapalombella Amber L Gordon Asha Ramanunni Kristie A Blum Jeffrey Jones Xiaoli Zhang Brian J Lannutti Kamal D Puri Natarajan Muthusamy John C Byrd Amy J Johnson

In patients with chronic lymphocytic leukemia (CLL), lenalidomide can promote humoral immune responses but also induces a distinct disease-specific toxicity of tumor flare and cytokine release. These CLL-specific events result from increased expression of costimulatory molecules on B cells. Here we demonstrate that lenalidomide activation of CLL cells depends on the phosphatidylinositol 3-kinas...

2018
Luca Arcaini Thierry Lamy Jan Walewski David Belada Jiri Mayer John Radford Wojciech Jurczak Franck Morschhauser Julia Alexeeva Simon Rule José Cabeçadas Elias Campo Stefano A Pileri Tsvetan Biyukov Meera Patturajan Marie-Laure Casadebaig Bravo Marek Trnĕný

In the mantle cell lymphoma (MCL)-002 study, lenalidomide demonstrated significantly improved median progression-free survival (PFS) compared with investigator's choice (IC) in patients with relapsed/refractory MCL. Here we present the long-term follow-up data and results of preplanned subgroup exploratory analyses from MCL-002 to evaluate the potential impact of demographic factors, baseline c...

Journal: :British journal of haematology 2015
Parisa Asvadi Andrew Cuddihy Rosanne D Dunn Vivien Jiang Mae X Wong Darren R Jones Tiffany Khong Andrew Spencer

MDX-1097 is an antibody specific for a unique B cell antigen called kappa myeloma antigen (KMA) that consists of cell membrane-associated free kappa light chain (κFLC). KMA was detected on kappa human multiple myeloma cell lines (κHMCLs), on plasma cells (PCs) from kappa multiple myeloma (κMM) patients and on κPC dyscrasia tissue cryosections. In primary κMM samples, KMA was present on CD38+ ce...

2015
Abdallah Abou Zahr Ehab Saad Aldin Rami S Komrokji Amer M Zeidan

Myelodysplastic syndromes (MDS) represent a heterogeneous group of acquired clonal hematopoietic disorders characterized by peripheral blood cytopenias, paradoxical BM hypercellularity, ineffective hematopoiesis, and increased risk of leukemic transformation. Risk stratification, using different prognostic scores and markers, is at the core of MDS management. Deletion 5q [del(5q)] MDS is a dist...

Journal: :Blood 2010
Umit Tapan David C Seldin Kathleen T Finn Salli Fennessey Anthony Shelton Jerome B Zeldis Vaishali Sanchorawala

The combination of lenalidomide and dexamethasone can produce hematologic responses in previously treated patients with AL amyloidosis.1 Since this prospective study (ClinicalTrials.gov: NCT00091260) was initiated, NT-proBNP and BNP have been found to be useful biomarkers for cardiac involvement, prognosis, and response to therapy in patients with AL amyloidosis.2-5 Here we report on the retros...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2006
R Baz E Walker M A Karam T K Choueiri R A Jawde K Bruening J Reed B Faiman Y Ellis C Brand G Srkalovic S Andresen R Knight J Zeldis M A Hussein

BACKGROUND Lenalidomide is active and well tolerated in relapsed and refractory multiple myeloma. We conducted a phase I/II trial of the combination of lenalidomide and chemotherapy to evaluate the safety and efficacy of the combination. METHODS The 62 patients enrolled received liposomal doxorubicin 40 mg/m(2) i.v. and vincristine 2 mg i.v. on day 1, dexamethasone 40 mg p.o. on days 1-4 (DVd...

2011
Annunziata De Luisi Arianna Ferrucci Addolorata M.L. Coluccia Roberto Ria Michele Moschetta Emanuela de Luca Luisa Pieroni Michele Maffia Andrea Urbani Giulia Di Pietro Attilio Guarini Girolamo Ranieri Paolo Ditonno Simona Berardi Antonella Caivano Antonio Basile Nicola Cascavilla Silvana Capalbo Giovanni Quarta Franco Dammacco Domenico Ribatti Angelo Vacca

Purpose: To determine the in vivo and in vitro antiangiogenic power of lenalidomide, a "lead compound" of IMiD immunomodulatory drugs in bone marrow (BM) endothelial cells (EC) of patients with multiple myeloma (MM) in active phase (MMEC). Experimental Design: The antiangiogenic effect in vivowas studied using the chorioallantoicmembrane (CAM) assay. Functional studies in vitro (angiogenesis, "...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2013
Chris Mahony Lynda Erskine Jennifer Niven Nigel H Greig William Douglas Figg Neil Vargesson

Thalidomide and its analog, Lenalidomide, are in current use clinically for treatment of multiple myeloma, complications of leprosy and cancers. An additional analog, Pomalidomide, has recently been licensed for treatment of multiple myeloma, and is purported to be clinically more potent than either Thalidomide or Lenalidomide. Using a combination of zebrafish and chicken embryos together with ...

2010
Inga Mandac Slobodanka Ostojic Kolonic

BACKGROUND A 24-year-old female patient was diagnosed with classic Hodgkin's lymphoma in clinical stage II, and combination chemotherapy followed by radiotherapy was initiated. During the following 5 years, the disease progressed despite several standard therapeutic approaches, including autologous and allogeneic stem cell transplantation. METHODS Lenalidomide (25 mg daily) treatment was then...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید